Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Moshe Tishler

Showing results (21-30 of 23) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 23 results.
The Israel Medical Association Journal : IMAJ|April 10, 2018
Effect of Tocilizumab on Fatigue and Bone Mineral Density in Patients with Rheumatoid ArthritisMahmoud Abu-Shakra, Devy Zisman, Alexandra Balbir-Gurman, et al.
Arthritis Research & Therapy|November 15, 2006
Methotrexate enhances the anti-inflammatory effect of CF101 via up-regulation of the A3 adenosine receptor expressionAvivit Ochaion, Sara Bar-Yehuda, Shira Cohn, et al.
The Journal of Rheumatology|December 1, 2007
Clinical evidence for utilization of the A3 adenosine receptor as a target to treat rheumatoid arthritis: data from a phase II clinical trialMichael H Silverman, Vibeke Strand, Doron Markovits, et al.
Pageof 3

Showing results (21-30 of 23) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 23 results.
The Israel Medical Association Journal : IMAJ|April 10, 2018
Effect of Tocilizumab on Fatigue and Bone Mineral Density in Patients with Rheumatoid ArthritisMahmoud Abu-Shakra, Devy Zisman, Alexandra Balbir-Gurman, et al.
Arthritis Research & Therapy|November 15, 2006
Methotrexate enhances the anti-inflammatory effect of CF101 via up-regulation of the A3 adenosine receptor expressionAvivit Ochaion, Sara Bar-Yehuda, Shira Cohn, et al.
The Journal of Rheumatology|December 1, 2007
Clinical evidence for utilization of the A3 adenosine receptor as a target to treat rheumatoid arthritis: data from a phase II clinical trialMichael H Silverman, Vibeke Strand, Doron Markovits, et al.
Pageof 3